Related Experiment Video
Updated: Jan 14, 2026

Author Spotlight: Repetitive Transcranial Magnetic Stimulation Combined with Movement Observation in Cerebral Palsy
Published on: August 9, 2024
Ofatumumab in pediatric multiple sclerosis: a case series.
Wenlin Wu1, Yanping Ran1, Chi Hou1
1Department of Neurology, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou City, Guangdong Province, P.R. China.
Ofatumumab (OFA) shows promise for treating pediatric multiple sclerosis (MS). This small study found OFA was well-tolerated and prevented relapses in young MS patients, suggesting potential benefits for this condition.
Area of Science:
- Neurology
- Immunology
Background:
- Pediatric-onset multiple sclerosis (POMS) is a chronic CNS demyelinating disorder affecting ~5% of MS cases.
- B cells are implicated in POMS pathogenesis, making B-cell targeted therapies a focus for relapse prevention.
More Related Videos
Related Concept Videos
Treatment Resistant Cancers
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Pharmacokinetics in Pediatric Patients: Drug Excretion
Pharmacokinetics in Pediatric Patients: Drug Distribution
Pharmacokinetics in Pediatric Patients: Drug Metabolism
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions

![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)